Skip to main content

Table 1 Regorafenib inhibits the growth of patient-derived gastric cancer xenograft models

From: Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

Xenograft model Treatment Mean ± SE tumor weight (g) Tumor growth inhibition (%)a p value versus vehicle
GC09-0109 Vehicle 1.14 (0.12)   
Reg 5 0.21 (0.03) 81.4 <0.001
Reg 10 0.17 (0.02) 84.9 <0.001
Reg 15 0.14 (0.02) 88.1 <0.001
GC28-1107 Vehicle 1.72 (0.16)   
Reg 5 0.48 (0.06) 72.4 <0.001
Reg 10 0.39 (0.06) 77.6 <0.001
Reg 15 0.21 (0.03) 88.0 <0.001
GC09-0109 Vehicle 0.92 (0.05)   
Reg 10 0.14 (0.01) 84.9 <0.01
GC22-0808 Vehicle 2.55 (0.27)   
Reg 10 0.11 (0.01) 95.9 <0.001
GC17-0409 Vehicle 2.03 (0.22)   
Reg 10 0.36 (0.05) 82.4 <0.001
GC10-0608 Vehicle 3.11 (0.35)   
Reg 10 0.31 (0.04) 90.0 <0.001
GC28-1107 Vehicle 1.40 (0.12)   
Reg 10 0.40 (0.02) 71.5 <0.001
GC23-0909 Vehicle 1.73 (0.11)   
Reg 10 0.22 (0.02) 87.0 <0.001
GC30-0309 Vehicle 3.48 (0.28)   
Reg 10 0.59 (0.07) 83.0 <0.001
GC05-0208B Vehicle 2.17 (0.10)   
Reg 10 0.49 (0.03) 77.6 <0.001
  1. Reg 5: regorafenib 5 mg/kg/day; Reg 10: regorafenib 10 mg/kg/day; Reg 15: regorafenib 15 mg/kg/day
  2. aTumor growth inhibition based on the difference in tumor weight between vehicle and regorafenib